These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34754394)

  • 41. Donor one‑carbon metabolism gene single nucleotide polymorphisms predict the susceptibility of cancer recurrence after liver transplantation.
    Wang C; Lu D; Ling Q; Chen J; Liu Z; Guo H; Xu X; Zheng S
    Gene; 2019 Mar; 689():97-101. PubMed ID: 30529095
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early tacrolimus exposure does not impact long-term outcomes after liver transplantation.
    Gastaca M; Ruiz P; Bustamante J; Martinez-Indart L; Ventoso A; Fernandez JR; Palomares I; Prieto M; Testillano M; Salvador P; Senosiain M; Suárez MJ; Valdivieso A
    World J Hepatol; 2021 Mar; 13(3):362-374. PubMed ID: 33815678
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of autotransfusion system on tumor recurrence and survival in hepatocellular carcinoma patients.
    Akbulut S; Kayaalp C; Yilmaz M; Ince V; Ozgor D; Karabulut K; Eris C; Toprak HI; Aydin C; Yilmaz S
    World J Gastroenterol; 2013 Mar; 19(10):1625-31. PubMed ID: 23538988
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma.
    Guo JH; Liu SX; Gao S; Kou FX; Zhang X; Wu D; Li XT; Chen H; Wang XD; Liu P; Zhang PJ; Xu HF; Cao G; Zhu LZ; Yang RJ; Zhu X
    World J Gastroenterol; 2020 Jul; 26(27):3975-3988. PubMed ID: 32774071
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pulmonary Resection for Metastasis of Hepatocellular Carcinoma Recurring After Liver Transplant: An Italian Multicenter Experience.
    Invenizzi F; Iavarone M; Donato MF; Mazzucco A; Torre M; Conforti S; Rimessi A; Zavaglia C; Schiavon M; Comacchio G; Rea F; Boetto R; Cillo U; Dondossola D; De Carlis L; Lampertico P; Nosotti M; Mendogni P
    Front Oncol; 2020; 10():381. PubMed ID: 32351877
    [No Abstract]   [Full Text] [Related]  

  • 46. Steroid elimination within 24 hours after orthotopic liver transplantation: effectiveness and tolerability.
    Wu LW; Guo ZY; Tai Q; Ju WQ; Wang DP; Hu AB; Zhu XF; He XS
    Hepatobiliary Pancreat Dis Int; 2012 Apr; 11(2):137-42. PubMed ID: 22484580
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of Liver Transplant on Long-term Disease-Free Survival in Children With Hepatoblastoma and Hepatocellular Cancer.
    Pham TA; Gallo AM; Concepcion W; Esquivel CO; Bonham CA
    JAMA Surg; 2015 Dec; 150(12):1150-8. PubMed ID: 26308249
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.
    Sharma P; Welch K; Hussain H; Pelletier SJ; Fontana RJ; Marrero J; Merion RM
    Dig Dis Sci; 2012 Mar; 57(3):806-12. PubMed ID: 21953139
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.
    Chiorean EG; Ramasubbaiah R; Yu M; Picus J; Bufill JA; Tong Y; Coleman N; Johnston EL; Currie C; Loehrer PJ
    Oncologist; 2012; 17(1):13. PubMed ID: 22210086
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Single-Center Experience of Recurrence Patterns and Survival Analyses of Patients With Hepatocellular Carcinoma and Liver Transplant.
    Rahatli S; Ayvazoglu Soy EH; Oguz A; Altundag O; Moray G; Haberal M
    Exp Clin Transplant; 2020 Apr; 18(2):201-205. PubMed ID: 32279656
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes.
    Younossi ZM; Stepanova M; Saab S; Ahmed A; Lam B; Srishord M; Venkatesan C; Wai H; Henry L
    J Viral Hepat; 2016 Jan; 23(1):53-61. PubMed ID: 26289820
    [TBL] [Abstract][Full Text] [Related]  

  • 52. No apparent benefit of preemptive sorafenib therapy in liver transplant recipients with advanced hepatocellular carcinoma on explant.
    Satapathy SK; Das K; Kocak M; Helmick RA; Eason JD; Nair SP; Vanatta JM
    Clin Transplant; 2018 May; 32(5):e13246. PubMed ID: 29577449
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Excellent post-transplant survival in patients with intermediate stage hepatocellular carcinoma responding to neoadjuvant therapy.
    Finkenstedt A; Vikoler A; Portenkirchner M; Mülleder K; Maglione M; Margreiter C; Moser P; Vogel W; Bale R; Freund M; Luger A; Tilg H; Petersen J; Schneeberger S; Graziadei I; Zoller H; Glodny B
    Liver Int; 2016 May; 36(5):688-95. PubMed ID: 26386273
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A multicenter randomized clinical trial evaluating interleukin-2 activated hematopoietic stem cell transplantation and post-transplant IL-2 for high risk breast cancer patients.
    Isaacs C; Slack R; Gehan E; Ballen K; Boccia R; Areman E; Kramer R; Hayes DF; Herscowitz H; Lippman M
    Breast Cancer Res Treat; 2005 Sep; 93(2):125-34. PubMed ID: 16187232
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments.
    He SL; Shen J; Sun XJ; Zhu XJ; Liu LM; Dong JC
    World J Gastroenterol; 2013 Jul; 19(28):4552-8. PubMed ID: 23901232
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis.
    Sasaki K; Firl DJ; Hashimoto K; Fujiki M; Diago-Uso T; Quintini C; Eghtesad B; Fung JJ; Aucejo FN; Miller CM
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):595-603. PubMed ID: 28546007
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Equal overall rejection rate in pre-transplant flow-cytometric cross-match negative and positive adult recipients in liver transplantation.
    Matinlauri IH; Höckerstedt KA; Isoniemi HM
    Clin Transplant; 2005 Oct; 19(5):626-31. PubMed ID: 16146554
    [TBL] [Abstract][Full Text] [Related]  

  • 58. LIVER TRANSPLANTATION: TACROLIMUS BLOOD LEVELS VARIATION AND SURVIVAL, REJECTION AND DEATH OUTCOMES.
    Maciel NB; Schwambach KH; Blatt CR
    Arq Gastroenterol; 2021; 58(3):370-376. PubMed ID: 34705973
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
    Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
    Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current strategies for preventing the recurrence of hepatocellular carcinoma after liver transplantation.
    Wang ZY; Geng L; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2015 Apr; 14(2):145-9. PubMed ID: 25865686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.